What is Psyomics?
Founded in March 2015 by Professor Sabine Bahn of the University of Cambridge and CEO Dan Cowell, Psyomics is dedicated to enhancing the speed and accuracy of identifying and diagnosing mental health challenges. The company leverages advanced technology and scientific expertise to address critical needs in mental health assessment, positioning itself as a key player in the health technology sector.
How much funding has Psyomics raised?
Psyomics has raised a total of $10M across 3 funding rounds:
Unspecified
$2M
Unspecified
$2.9M
Other Financing Round
$5.1M
Unspecified (2020): $2M with participation from Martlet, Jonathan Milner, Cambridge Enterprise, and Parkwalk Advisors Limited
Unspecified (2022): $2.9M led by Parkwalk
Other Financing Round (2024): $5.1M supported by Parkwalk Advisors
Key Investors in Psyomics
Martlet
Martlet is an angel investment group focused on early-stage companies, likely providing seed capital and strategic guidance to promising startups.
Cambridge Enterprise
Cambridge Enterprise is the commercialization arm of the University of Cambridge, investing in and supporting spin-out companies that emerge from university research.
Parkwalk Advisors Limited
Parkwalk Advisors Limited is a prominent investor in university spinouts, specializing in deeptech innovations and providing crucial funding and expertise to help academic ventures achieve commercial success.
What's next for Psyomics?
With the recent major strategic investment, Psyomics is poised for accelerated growth and further development of its diagnostic solutions. This capital infusion is expected to fuel expansion into new markets, enhance research and development capabilities, and solidify its position in the competitive health tech landscape. The company's trajectory suggests a focus on scaling its operations and broadening the impact of its innovative mental health identification tools.
See full Psyomics company page
